Back to Authors

Cuthbert, Carla

Mayo Clinic

Centers for Disease Control and Prevention

Citations 3

Can Incorporating Molecular Testing Improve the Accuracy of Newborn Screening for Congenital Adrenal Hyperplasia?
Sarafoglou, Kyriakie , Wolf, Carrie, Lorentz, Cindy Pham, Lteif, Aida, Kyllo, Jennifer, Radloff, Gretchen A., Detwiler, Zachary, Cuthbert, Carla, Grosse, Scott D. , Greene, Christopher N. , Cordovado, Suzanne K., Grosse, Scott D , Gaviglio, Amy , Detwiler, Zachary , Hodges, James S.

The Journal of Clinical Endocrinology & Metabolism | May 3, 2024 | Volume: 110 | Issue: 4 | Pages: e1194-e1203

10.1210/clinem/dgae297 Get It

Abstract Context Single-tier newborn screening (NBS) for congenital adrenal hyperplasia (CAH) using 17-hydroxyprogesterone (17OHP) measured by fluoroimmunoassay (FIA) in samples collected at 24 to 48 hours produces a high false-positive rate (FPR). Second-tier steroid testing can reduce the FPR and has been widely implemented. Objective We investigated the accuracy of an alternative multitier CAH NBS protocol that incorporates molecular testing of the CYP21A2 gene and reduces the first-tier 17OHP cutoff to minimize missed cases. Methods We create a Minnesota-specific CYP21A2 pathogenic variants panel; developed a rapid, high-throughput multiplex, allele-specific-primer-extension assay; and performed a 1-year retrospective analysis of Minnesota NBS results comparing metrics between a conventional steroid-based 2-tier protocol and a molecular-based multitier NBS protocol, applied post hoc. Results CYP21A2 gene sequencing of 103 Minnesota families resulted in a Minnesota-specific panel of 21 pathogenic variants. The Centers for Disease Control and Prevention created a molecular assay with 100% accuracy and reproducibility. Two-tier steroid-based screening of 68 659 live births during 2015 resulted in 2 false negatives (FNs), 91 FPs, and 1 true positive (TP). A 3-tier protocol with a lower first-tier steroid cutoff, second-tier 21-variant CYP21A2 panel, and third-tier CYP21A2 sequencing would have resulted in 0 FNs, 52 FPs, and 3 TPs. Conclusion Incorporation of molecular testing could improve the accuracy of CAH NBS, although some distinct challenges of molecular testing may need to be considered before implementation by NBS programs.
Leadership and Management Training for Residents and Fellows: A Curriculum for Future Medical Directors
Hemmer, Patrick R., Karon, Brad S. , Hernandez, James S , Cuthbert, Carla, Fidler, Mary E., Tazelaar, Henry D. , Tazelaar, Henry D.

Archives of Pathology & Laboratory Medicine | February 11, 2021 | Volume: 131 | Issue: 4 | Pages: 610-614

10.5858/2007-131-610-lamtfr Get It

Abstract Context. —Management of laboratories and pathology practices is increasingly complex. Residents and fellows in laboratory medicine and pathology need more structured curricula in leadership and management (L&M) training to function as medical and laboratory directors. Objective. —To define a curriculum that provides basic competency in L&M for residents and fellows in pathology. Design. —A year-long formal L&M course included didactic lectures, interactive sessions, case scenarios, team-building exercises, formal team presentations (capstone project), and precourse and postcourse assessment of L&M knowledge. The curriculum meets requirements of American College of Graduate Medical Education and supports goals for leadership training of the College of American Pathologists. Participants evaluated (5-point scale) the content and speakers of all sessions. Trainees were evaluated after considering postcourse examination results, quality of the capstone presentation, and a global assessment. Results. —The 5 non-capstone sessions received evaluation scores ranging from 4.4 (informatics) to 5 (L&M basics). Postcourse test scores showed significant improvement when compared with the pretest scores for the 2003– 2004 and 2004–2005 trainee cohorts. Conclusions. —Short-term results indicate that the course described improves trainee knowledge of L&M issues.
Determination of Total Homocysteine, Methylmalonic Acid, and 2-Methylcitric Acid in Dried Blood Spots by Tandem Mass Spectrometry
Turgeon, Coleman , Magera, Mark J , Cuthbert, Carla, Loken, Perry R , Gavrilov, Dimitar K. , Tortorelli, Silvia , Raymond, Kimiyo , Oglesbee, Devin , Rinaldo, Piero, Matern, Dietrich , Gavrilov, Dimitar , Oglesbee, Devin

Clinical Chemistry | September 1, 2010 | Volume: 56 | Issue: 11 | Pages: 1686-1695

10.1373/clinchem.2010.148957 Get It

BACKGROUNDNewborn screening (NBS) for inborn errors of propionate, methionine, and cobalamin metabolism relies on finding abnormal concentrations of methionine and propionylcarnitine. These analytes are not specific for these conditions and lead to frequent false-positive results. More specific markers are total homocysteine (tHCY), methylmalonic acid (MMA), and methylcitric acid (MCA), but these markers are not detected by current NBS methods. To improve this situation, we developed a method for the detection of tHCY, MMA, and MCA in dried blood spots (DBSs) by liquid chromatography–tandem mass spectrometry (LC-MS/MS).METHODSThe analytes were extracted from a single 4.8-mm DBS punch with acetonitrile:water:formic acid (59:41:0.42) containing dithiothreitol and isotopically labeled standards (d3-MMA, d3-MCA, d8-homocystine). The extract was dried and treated with 3 N HCl in n-butanol to form butylesters. After evaporation of the butanol, the residue was reconstituted and centrifuged and the supernatant was subjected to LC-MS/MS analysis. Algorithms were developed to apply this method as an efficient and effective second-tier assay on samples with abnormal results by primary screening.RESULTSThe 99th percentiles determined from the analysis of 200 control DBSs for MMA, MCA, and HCY were 1.5, 0.5, and 9.8 μmol/L, respectively. Since 2005, prospective application of this second-tier analysis to 2.3% of all NBS samples led to the identification of 13 affected infants.CONCLUSIONSApplication of this assay reduced the false-positive rate and improved the positive predictive value of NBS for conditions associated with abnormal propionylcarnitine and methionine concentrations.